Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 1;1865(8):1982-1991.
doi: 10.1016/j.bbadis.2018.10.019. Epub 2018 Oct 20.

The impact of histone post-translational modifications in neurodegenerative diseases

Samantha N Cobos  1 , Seth A Bennett  2 , Mariana P Torrente  3
Affiliations
Review

The impact of histone post-translational modifications in neurodegenerative diseases

Samantha N Cobos et al. Biochim Biophys Acta Mol Basis Dis. .

Abstract

Every year, neurodegenerative disorders take more than 5000 lives in the US alone. Cures have not yet been found for many of the multitude of neuropathies. The majority of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Parkinson's disease (PD) cases have no known genetic basis. Thus, it is evident that contemporary genetic approaches have failed to explain the etiology or etiologies of ALS/FTD and PD. Recent investigations have explored the potential role of epigenetic mechanisms in disease development. Epigenetics comprises heritable changes in gene utilization that are not derived from changes in the genome. A main epigenetic mechanism involves the post-translational modification of histones. Increased knowledge of the epigenomic landscape of neurodegenerative diseases would not only further our understanding of the disease pathologies, but also lead to the development of treatments able to halt their progress. Here, we review recent advances on the association of histone post-translational modifications with ALS, FTD, PD and several ataxias.

Keywords: Amyotrophic lateral sclerosis; Epigenetics; Friedreich's ataxia; Frontotemporal dementia; Histones; Neurodegeneration; Neurodegenerative disease; Parkinson's disease; Post translational modifications; Spinocerebellar ataxia.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Notable histone modifications linked to FUS, TDP-43, and C9orf72 in ALS
Figure 2.
Figure 2.
Notable histone modifications linked to FUS and Tau in FTD
Figure 3.
Figure 3.
Notable histone modifications linked to α-synuclein and dopamine depletion in PD
Figure 4.
Figure 4.
Notable histone modifications linked to ATXN8 in SCA8 and Frataxin in FRDA
See this image and copyright information in PMC

References

    1. Gibson SB, Figueroa KP, Bromberg MB, Pulst S-M, and Cannon-Albright L, “Familial clustering of ALS in a population-based resource,” Neurology, vol. 82, no. 1, pp. 17–22, Jan. 2014. - PMC - PubMed
    1. Ferrari R, Kapogiannis D, Huey ED, and Momeni P, “FTD and ALS: a tale of two diseases,” Curr. Alzheimer Res, vol. 8, no. 3, pp. 273–294, May 2011. - PMC - PubMed
    1. Globas C et al., “Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6,” Mov. Disord, vol. 23, no. 15, pp. 2232–2238. - PubMed
    1. Poewe W et al., “Parkinson disease,” Nat. Rev. Dis. Primer, vol. 3, p. 17013, Mar. 2017. - PubMed
    1. Martin S, Al Khleifat A, and Al-Chalabi A, “What causes amyotrophic lateral sclerosis?,” F1000Research, vol. 6, Mar. 2017. - PMC - PubMed

Publication types